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Neurodegenerative diseases (ND) are characterized by the progressive loss of neuronal
structure or function mostly associated with neuronal death. The presence of the
blood–brain barrier (BBB) is considered themain obstacle that prevents the penetration of
almost all drugs rendering the diseases untreatable. Currently, one of the most promising
approaches for drug delivery to the brain is by employing endogenous transcytosis
to improve endothelial cell uptake. This study aimed to exploit this potential route of
enhanced drug uptake through the design and characterization of low generations
lysine dendrons with further functionalization of dendron with ApoE-derived peptide
(AEP) ligand to improve cellular uptake and targeting of delivery to the brain. Dendrons
and peptide were synthesized using solid phase peptide chemistry and the products
were characterized by mass spectrometry and high performance liquid chromatography
which confirmed the successful synthesis of dendrons and functionalization with the
AEP. Cell viability and lactate dehydrogenase release were conducted to study the
cytotoxicity of the materials against an immortalized brain endothelial cell line (bEnd.3)
which demonstrated that no toxicity was seen at the concentration range used (up to
400µM) for up to 48 h incubation. Cellular uptake of the synthesized molecules was
examined using confocal microscopy and flow cytometer which clearly showed the
cellular uptake of the dendronised carrier systems and that the highest percentage
of cellular uptake was achieved with the AEP-functionalized dendron. This study has
therefore demonstrated the successful synthesis of dendronised carrier systems with
the potential to act as carriers for improved delivery and targeting the brain.
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INTRODUCTION
The early diagnosis and efficacious treatment of neurodegenerative diseases (NDs), including
Alzheimer’s disease, Parkinson’s disease and multiple sclerosis, are significantly compromised by
the presence of the blood–brain barrier (BBB), a membranemade of astrocytes and endothelial cells
connected by tight junctions that prevents the sufficient penetration of almost all drugs, genes and
imaging agents to the brain (Re et al., 2012; Wyss, 2016). Several approaches have been considered
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to penetrate the BBB including temporary disruption or
opening of the BBB by chemical methods. However, these
strategies are limited by the lack of selectivity that allows
the penetration of other unwanted substances in the brain
(Banks, 2012). The chemical modification of drugs with
functional groups facilitating cell internalization have also
been proposed (Wermuth et al., 2015), but their applicability
is limited to the suitability of the drug properties for
chemical derivatisation and to the alteration of their therapeutic
efficacy (Chen and Liu, 2012).
Transport-vector strategies have recently been developed to
deliver bioactive molecules with low BBB permeability to the
brain (Kumar et al., 2015). These strategies capitalize either
on the temporary destabilization of the tight junction sealing
the extracellular endothelial space or on the internalization of
macromolecules by the endothelial cells (Khawli and Prabhu,
2013). In the latter approach, the design of the transport-vector is
based on the exploitation of the two main transcytosis pathways:
(i) the adsorptive-mediated transcytosis (AMT) relying on the
ability of hydrophobic molecules to penetrate the phospholipidic
plasmalemma (Herve et al., 2008) and (ii) the receptor-mediated
transcytosis (RMT) exploiting the biospecific recognition of
ligands by cell receptors involved in the transport of molecules
essential to the brain physiology (Chen and Liu, 2012).
The use of these carriers is one of the most promising as it
has the potential of combining effective transport to the lack
of drawbacks such as disruption of the BBB integrity and cell
toxicity (Khawli and Prabhu, 2013). Therefore, these concepts
have been applied to a range of widely recognized drug delivery
system; these include micelles, vesicle, liposomes, polymers,
dendrimers and nanoparticles (Sahoo et al., 2007). It is postulated
that, while these drug delivery systems improve drug solubility,
payload (Tiwari et al., 2012) and dosage (Sahoo et al., 2007),
their coupling with molecules able to exploit AMT or RMT
will enhance their BBB penetration. The combination of these
properties will provide a carrier platform suitable for the delivery
of various types of drugs or diagnostics (Re et al., 2012).
It is understood that the integration of an AMT- or RMT-
specific molecule in the carrier needs to be conceived to enhance
its presentation to the cell membrane and receptors while
maintaining the ability to form a stable complex with the
transported drug.
Dendrimers are hyperbranched polymeric macromolecules
that can be synthesized from different monomers to obtain
structures of well-defined order, size and polydispersity index
(Heather et al., 2011). The high density of their terminal
functional groups is one of the key properties as it provides
multiple attachment sites for the complexation of drugs
or other bioactive molecules. In addition, dendrimers are
metabolized by cellular hydrolytic enzymes and completely
biodegraded into their non-toxic building monomers (Sadekar
et al., 2013). Because of these properties, dendrimers have
been proposed as nanocarriers with a high therapeutic
potential (Khawli and Prabhu, 2013); they have efficiently
been used in many pharmaceutical and personal care
applications (Sahoo et al., 2007) and for applications in cancer
therapy and imaging (Lee and Nan, 2012). Polyamidoamine
(PAMAM) dendrimers conjugated with the anticancer
drug, camptothecin, have been shown to enhance the drug
solubility and to increase its bioavailability at the target
tissue (Sadekar et al., 2013).
Noticeably, it has also been observed that PAMAM
dendrimers complexed with non-steroidal anti-inflammatory
drugs such as ketoprofen and indomethacin improved the
drug permeation through the skin (Cheng et al., 2007) and
that in the case of oral drug delivery they can cross cell
membranes (Patri and Simanek, 2012). Likewise, it was also
found that dendrimer-ibuprofen complexes were able to enter
the lung cells more rapidly when compared with the free drug
(Kolhe et al., 2003) and that the conjugation of doxorubicin
to a polyethyleneglycol (PEG) dendrimer enhanced cellular
uptake by the brain and reduced tumor volume of glioma
spheroids (Li et al., 2012; Xu et al., 2014).
However, all these drug carrier systems were not specifically
designed to guarantee enhanced interaction with the cell
plasmalemma or bio-specificity. Bio-specificity has recently been
pursued for a number of applications by the introduction of
a novel class of dendrimer derivatives, the dendrons. These
are macromolecules with a tree-like structure able to present
different functionalities at their molecular root and at their
uppermost branching terminals (Meikle et al., 2011). The dual
functionality enables the carriers to form stable and specific
complexes with bioactive molecules (Meikle et al., 2016; Perugini
et al., 2018) and/or magnetic resonance contrast agents (i.e.,
magnetic nanoparticles) while enhancing cell internalization
processes (Maggio et al., 2016). These specific designs of
dendrons are made possible by the solid phase synthesis
of poly(epsilon-Lysine) branched peptides that ensures the
controlled presentation of the desired functionalities in terms of
both orientation and spacing (Meikle et al., 2011).
The aim of this work was to develop AMT- and RMT-
competent poly(epsilon-Lysine) dendrons as a carrier platform
for the delivery of bioactive molecules and contrast agents
to the brain by enhanced BBB endothelial cells targeting
and internalization.
In the case of AMT-competent dendrons a hydrophobic
amino acid, the phenylalanine, was integrated at the root of the
dendron in the view of enhancing the hydrophobic interaction
of the carrier with the phospholipidic membrane. Whereas
in the case of RMT-competent dendrons, the root of the
dendron integrated a peptide sequence (LRKLRKRLLR)
(Sauer et al., 2005; Gobbi et al., 2010). This peptide
sequence has been previously identified as an analogue
of the apolipoprotein E (ApoE), a protein recognized
by the low density lipoprotein receptor (LDLr) that is a
receptor involved in the transcytosis of molecules across the
BBB (Xiao and Gan, 2013; Molino et al., 2017)
The present work focussed on achieving a high level
of purity of the synthesized macromolecules and on the
assessment of the impact of their size and AMT or RMT
functionality on the efficiency of BBB endothelial cells
internalization process.
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MATERIALS AND METHODS
Synthesis of Delivery Systems
Poly(epsilon-Lysine) dendrons with branching generation 0 (G0,
two exposed amino groups) and G1 (4 exposed amino groups)
were synthesized using a high-yield solid phase peptide synthesis
(SPPS) (Shin et al., 2005; Made et al., 2014) based on the use of a
microwave system (Biotage Initiator, UK). The synthesis of AMT-
competent dendrons included the integration of a Phenlyalanine
monomer at its molecular root (Figures 1A,B). In the case of
the G0 dendron an alternative RMT-competent formulation
was synthesized by integrating the ApoE-mimicking sequence,
LRKLRKRLLR in the dendron root (Figure 1C). Both types of
dendrons were assembled on a Tentagel NH2 resin previously
coupled with a Rink-amide-linker susceptible to cleavage and
necessary for the liberation of the dendron at the end of the
synthesis (Meikle et al., 2011). The dendron assembly on the solid
phase support was performed through different cycles each one
using 0.4 mmol of Fmoc-protected amino acids (Novabiochem,
UK) (Figure 2). In the case of the AMT-competent dendron the
root was achieved by the grafting of a Fmoc-Phe-OH followed
by the assembling of Fmoc-lys(Fmoc)-OH in cycles necessary for
either a G0 and G1 branching. Whereas, a sequence of Fmoc-
Leu-OH, Fmoc-Arg-OH, Fmoc-Lys(Boc)-OH, Fmoc-Leu-OH,
Fmoc-Arg-OH, Fmoc-Lys(Boc)-OH, Fmoc-Arg-OH, Fmoc-Leu-
OH, Fmoc-Leu-OH, Fmoc-Arg-OH consecutively were used for
the synthesis of the APE linear peptide at the root of the RMT-
competent dendron. The synthesis protocol included coupling
of the Fmoc amino acid, its deprotection from the Fmoc group
and cleavage of the final product from the resin as previously
described (Meikle et al., 2011; Al-azzawi, 2017). The cleaved
mixture was washed, filtered and collected in chilled diethylether.
After a series of centrifugation and washing steps with diethyl
ether, the precipitated peptides were collected and freeze dried.
In order to remove any impurities and undesired by-products, a
Zeba spin desalting column (Fisher scientific, UK) was used and
the final pure products were used for characterization and in vitro
cell experiments.
Characterization of Dendronised Delivery
Systems by Mass Spectrometry (MS)
The AMT-competent G0- and G1- dendrons as well as
the RMT-competent AEP-dendron were characterized by
electrospray/ionization-time of flight (ESI-TOF MS) (Bruker
Daltonics, UK) at high voltage (4 kV). The samples were
dissolved in methanol, then filtered using a 0.22µm filter and
injected into the spectrometer. In electrospray/ionization mode,
sample mass (m/z) gave rise to multiple charged ions labeled
with a number of charges (n) as (MW+nH)n+, where H is the
mass of a proton (1.008 Da).
Characterization of Dendronised Delivery
Systems by High Performance Liquid
Chromatography (HPLC)
Each sample was dissolved in methanol and filtered with
a 0.22µm filter before analysis. The analytical method
was performed using HPLC, diode array detector (Agilent
technology/1260 infinity, UK) with a Luna hydrophobic C18
column (150∗4.6mm) and a UV-detection wavelength of 223 nm,
the optimum wavelength for these peptide dendrons (Al-azzawi,
2017). The HPLC mobile phase consists of water/acetonitrile in
which the gradient of eluent was run from 75:25 to 25:75 water:
acetonitrile over 20 min.
Preparation of bEnd.3 Cell Line
The immortalized brain endothelial cell line, bEnd.3 (ATCC-
CRL-2299), and Dulbecco’s modified eagle’s medium (DMEM)
were obtained from ATCC (USA). The bEnd.3 cells were
cultured, according to ATCC-product sheet instruction, in
DMEM high glucose medium with L-pyruvate, containing
10 % (v/v) fetal bovine serum and 1% (v/v) of 500 U/ml
Penicillin/Streptomycin (Gibco, Germany). Cells were seeded
at a density of 5 × 104 cells per cm2 in 24-well plates then
incubated at 37◦C and 5% CO2 and the culture media was
replaced every 3 days.
Cytotoxicity Assays
Experiments were performed when cells reached confluence. A
range of concentrations (25, 50, 100, 150, 200, 300, and 400µM)
of each AMT-competent G0-, G1-dendron, and RMT-competent
AEP-dendron were used in each experiment.
The MTT [(4,5-Dimethylthiazol-2-yl)-3,5-diphenylformazan
thiazolyl blue tetrazolium] (Sigma Aldrich, UK) assay was
used to measure cell viability (Mosmann, 1983). After 24 and
48 h treatment exposure, the MTT assay was conducted and
the absorbance was measured at a wavelength of 540 nm by
spectrophotometry (Thermo Multiskan Ascent, UK). Readings
of 6 replicates were expressed as percentage of the untreated
control cells.
Lactate dehydrogenase (LDH) was measured using
Promega CytoTox96 R© non-radioactive cytotoxicity assay
kit (UK) after 24 and 48 h incubation. Absorbance was read
spectrophotometrically at 492 nm and converted to a percentage
of the total LDH released from the positive control (cells
subjected to complete lysis) for 6 replicates.
Cellular Uptake Studies
Cellular Uptake Examination by Laser Scanning
Confocal Microscopy (LSCM)
To study the cellular uptake of the designed delivery systems,
the AMT-competent G0- and G1-dendrons, and the RMT-
competent AEP-dendron were labeled with fluorescein-5-
isothiocyanate (FITC) (Sigma Aldrich, UK). The labeling was
performed by dark covalent coupling reaction with FITC solution
with 2 molar excess for each terminal amino group. The
products were washed with dichloromethane, methanol and
diethylether (Fisher scientific, UK), consecutively to remove any
unreacted substances.
The bEnd.3 cells were treated at confluence with FITC-
labeled products dissolved in DMEM and incubated for 1 h (the
appropriate incubation time for dendrons with this type of cell
line). The cells were then fixed with 3.7% (v/v) formalin, and
analyzed by LSCM (Leica TCS SP5, UK), using a 488-visible
laser source.
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FIGURE 1 | Chemical structure of (A) G0-dendron (chemical formula: C15H23N3O3, molecular weight (MW): 293.3 Da). (B) G1-dendron (chemical formula:
C27H47N7O5, MW: 549.7 Da). (C) AEP-dendron (chemical formula: C66H130N26O12, MW: 1479.9 Da). The encircled groups represent the free amino
terminal groups.
FIGURE 2 | Schematic diagram showing SPPS chemistry including coupling and deprotection of amino acids monomers for synthesis of G0-, G1-, and AEP-dendron.
Cellular Uptake Evaluation by Flow Cytometer
The bEnd.3 cells were cultured and treated at confluence
with 100 µL FITC-labeled products dissolved in DMEM
for 1 h. The cells were washed with phosphate buffer
solution twice and trypsinised and then harvested to
be analyzed using BD C6 sampler flow cytometer (BD
Accuri C6, Bioscience, UK). Samples of cells without
treatment were also included as a control, and the
analysis was carried out through the FL1-H channel for
FITC detection.
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FIGURE 3 | Mass spectrum of G0-dendron showing the main peak of 293.2 representing the exact MW of product.
FIGURE 4 | Mass spectrum of G1-dendron showing the main peak of 549.3 representing the exact MW of product with a peak seen at 275.1 with double charge at
0.75*104 intensity, represents the related ion of m/z = (549+1.008*2)/2.
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 5 March 2019 | Volume 7 | Article 49
Al-azzawi et al. Brain Endothelial Cells Targeting Dendrons
FIGURE 5 | Mass spectrum of AEP-dendron shows a peak seen at 740 with double charge at 1.75*105 intensity, representing the related ion of m/z =
(1,479+1.008*2)/2, whereas the peak 501with triple positive charge of intensity 1.3*105 refers to the theoretical MW (m/z = (1,479+1.008*3)/3).
Statistical Analysis
Mean values were calculated for the number of readings (n =
6) in each experiment and the error bars refer to the standard
deviation (SD). Results were statistically analyzed using one-way
ANOVAwith Tukey’s tests. Significant differences were identified
by a P-value < 0.05.
RESULTS
Characterization by Mass Spectrometry
Figure 3 shows the mass spectrum obtained for the AMT-
competent G0-dendron, the main peak at 293.2 Da matches
exactly the calculated theoretical MW of this molecule indicating
the successful synthesis of this dendron. Similarly, Figure 4
refers to the MW of the AMT-competent G1-dendron to be
549.3 Da which again matches the calculated MW of this
molecule. The mass spectrum of the RMT-competent AEP-
dendron presented in Figure 5 demonstrates the successful
synthesis and functionalization of the dendronised peptide with
a theoretical MW of 1,479 Da. The appearance of the peak 740
with double charge, and the peak 501 with a triple positive
charge, represent the related ions of the AEP-dendron. Other
peaks appearing in the spectra result from the ionization of
the molecule and the solvent or machine noise, as well as, the
related sodium salts formed due to interaction of ions with
glass vessels (Downard, 2004). However, the expected molecular
weights related to the peptides were clearly observed confirming
their synthesis.
Characterization by HPLC
The synthesized products including the AMT-competent G0-,
G1-dendrons, and the RMT-competent AEP-dendron as well as
the solvent (methanol) were analyzed by HPLC to characterize
the products. It can be noticed that only one large peak was
observed in each elution (Figure 6), other small peaks are
attributed to the solvent as shown in the elution of methanol
alone (Figure 6A). The absence of impurities throughout the
HPLC analysis suggested the complete synthesis of the product
and cleavage of the linker and resin from the peptide.
Cytotoxicity Studies
The MTT assay was performed after 24 and 48 h treatment
of confluent bEnd.3 cells with increasing concentrations of
AMT-competent G0- and G1-dendrons, and of RMT-competent
AEP-dendron. The results demonstrated no decrease in cell
metabolic activity below 78% when compared to the control
(Figure 7) suggesting that neither molecules, even at the
highest concentration tested (400µM) were toxic to these
cells (International-Standards, 2009). In addition, no significant
difference (P > 0.05) was seen between the corresponding
concentrations after 24 and 48 h treatments.
The results of the LDH assay supported the findings of the
MTT assay with low amounts of LDH released after bEnd.3 cells
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FIGURE 6 | HPLC analysis. (A) For Methanol only, (B) For G0-dendron in methanol. (C) For G1-dendron in methanol and (D) For AEP-dendron in methanol.
were treated with the AMT-competent G0- and G1-dendrons
and with the RMT-competent AEP-dendron in concentrations
up to 400µM for 24 and 48 h. For both incubation periods the
cell membrane lysis was below the 10% of the positive control
where cells were deliberately lysed with no significant difference
(P > 0.05) between the corresponding concentrations of both
periods (Figure 7).
Cellular Uptake by Brain Endothelium
Cellular Uptake Examination of Dendronised Delivery
Systems by LSCM
After 1 h treatment with FITC-labeled AMT-competent G0- and
G1-dendrons and RMT-competent AEP-dendron, the formalin-
fixed bEnd.3 cells were viewed by LSCM using a 488-visible
laser source. The micrographs clearly showed the accumulation
of green fluorescence inside the cells in comparison to the
control cells indicating successful cellular uptake of both AMT-
competent G0- and G1-dendrons and RMT-competent AEP-
dendron (Figure 8). The effect of FITC on the permeability of
the delivery systems was excluded by giving negative results when
incubated alone with cells (data not shown).
Assessment of the Cellular Uptake of Dendronised
Delivery Systems by Flow Cytometry
The uptake of FITC-labeled AMT-competent G0- and G1-
dendrons and RMT-competent AEP-dendron was quantitatively
analyzed via flow cytometry (Figures 9A,B). The results at 1 h
incubation of the carriers with confluent bEnd.3 cells revealed
that cellular uptake was 38.7% and 67.8% for the AMT-competent
G0- and G1-dendrons in comparison to the negative control
(untreated cells). On the other hand, the cellular uptake of
the RMT-competent AEP-functionalized dendron reached 90.7%
(Figure 9A). In addition, the analysis showed a clear shift of
the peaks associated with the AMT-competent G0- and G1-
dendrons, and RMT-competent AEP-dendron from that of
control untreated cells, with largest shift observed in the RMT-
competent AEP-dendron (Figure 9B). The greater the shift from
the control the greater is the cellular uptake of the molecule.
DISCUSSION
The effective and targeted delivery of therapeutics to the brain
in NDs remains a huge unsolved problem (Wyss, 2016). As
many therapeutics are unable to permeate in to the brain
endothelium, several strategies to improve the delivery of
molecules including drugs, genes and imaging agents to the CNS
have been developed including local injection or BBB opening or
enhancing the permeability across the barrier through targeted
delivery (Boer and Gaillard, 2007).
In recent years, therapeutic delivery to the brain in NDs has
focused on mechanisms that can use the endogenous transport
systems available on the BBB which are considered an effective
and safe way to deliver molecules into the brain. Indeed, certain
peptides and some macromolecules can pass through BBB via
transcytosis mechanisms either by physical adsorption on the cell
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FIGURE 7 | Cytotoxicity results after 24 and 48 h treatment of bEnd.3 cells with G0- and G1-dendron and AEP-dendron. The MTT levels were obtained by measuring
absorbance and the cell viability was calculated as a percentage in relation to control untreated cells. The LDH release of each was calculated as a percentage of
absorbance in relation to untreated, complete lysis control cells (100% lysis) with significantly difference to positive control (P < 0.001). The data represent mean ± SD
of n = 6.
membrane or by receptor mediation (Oller et al., 2016; Mager
et al., 2017). Generally, endocytosis in AMT is promoted by
the interaction of cationic molecules with phospholipids and
the glycocalyx at membrane forming vesicles which matures
to early endosomes and the molecule can subsequently be
degraded releasing the cargo. Whereas, internalization by RMT
is evoked by ligand-receptor interaction, which begins with
the formation of a caveolae followed by the delivery of the
receptor-ligand complex and transcytosis. In this regards, LDLrs
have been extensively exploited in receptor-mediated delivery
and signaling at the BBB (Oller et al., 2016). Upregulation
of the LDLr gene family at the BBB region, in comparison
with other endothelia, can support this hypothesis through the
recognition of Apo-E derived peptide (141–150 amino acids)
(Re et al., 2011; Wang et al., 2013).
Currently, dendrons offer an important non-invasive strategy
for drug delivery and targeting, arising from their structural
characteristics with the possibility of multi-functionalisation.
In the present study, positively-charged poly(epsilon-Lysine)
dendrons (G0 and G1) were used as a carrier system
with the potential to be efficiently functionalized at their
molecular root with a specific functionality promoting either
AMT or RMT, while their free terminal amine groups offer
multiple attachments for drug molecules or other bioactive
agents. Unlike other approaches, here the size of the carrier
and its branching was limited to either one Lysine residue
yielding two amino-terminal branches or to two Lysine
residues leading to the exposure of four amino-terminals.
This approach aimed to preserve the internalization potential
of dendrons while reducing the potential toxicity generated
by excessive positive charges. In addition, the presence of
the hydrophobic domain is deemed to be still beneficial
in the case of neutralization of the positive charge of the
dendron by interaction with the loaded drug. Indeed, this
level of branching is sufficient to support the transport
of non-steroideal anti-inflammatory drug across an in vitro
BBB model using a cultured bEnd.3 monolayer on Transwell
membrane (Al-Azzawi et al., 2018).
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FIGURE 8 | LSCM pictures of bEnd.3 cells after treatment with FITC-labeled G0-, G1-dendron and AEP-dendron and untreated control cells, showing clear
accumulation of green fluorescence inside the cells.
To achieve this aim, microwave Fmoc-based SPPS was
employed to synthesize dendrons and the AEP followed by the
functionalization of the dendron at its root with this synthesized
AEP (141-150) corresponding to the ApoE-binding domain with
LDLr (Re et al., 2011). This procedure ensures a high yield and
purity of the final product (Rodriguez et al., 2010). The type
of α-amino protecting group in amino acids has to be taken
into consideration to ensure the synthesis of the desired peptide.
For this reason, Fmoc-Lys(Boc)-OH, was used to obtain a linear
chain of AEP, whereas Fmoc-Lys(Fmoc)-OH was employed for
the branching of the peptide into a dendron structure. The
formation of the amide linkage is dependent upon the side-
chain protectors of amino acids which can ensure the chemical
reaction of Fmoc at the site of interest only. Therefore, using
the appropriate Fmoc type prevents unwanted reactions that
could result in the formation or incorporation of dipeptide
derivatives. Subsequently, it can help in the purification of the
final product due to a smaller amount of secondary products
(Made et al., 2014). In this work this was confirmed by the
mass spectrometry and HPLC analysis data which indicated the
successful synthesis of the desired peptides, matching previous
studies in which G3K-dendrimers were efficiently produced and
successfully functionalized with different bioactives using this
method (Meikle et al., 2011, 2016).
The success of any delivery system or biomaterial to be
used in drug or gene delivery relies on their cytocompatibility
and biodegradability properties (Svenson and Tomalia, 2005).
Based on MTT assay, up to the relatively high doses of
400µM of AMT-competent G0-, G1-dendrons, and RMT-
competent AEP-dendron maintained cell viability after 24 and
48 h above 70% indicating no considerable effect of these
novel carriers on mitochondrial function when compared to
control cells. Furthermore, the products did not show any
significant effect on cell membrane integrity according to
the cell lysis results obtained by LDH assays. These findings
indicate the biocompatibility of these synthesized products
and are consistent with other studies which have shown that
low generation dendrons and AEP-functionalized nanocarriers
display low cytotoxicity (Sauer et al., 2005). It has been shown
that lysine-modified dendrimers demonstrated low cytotoxicity
with high transfection efficiency on HepG2, Neuro 2A cell
lines, and primary rat vascular smooth muscle cells (Choi
et al., 2004). Furthermore, conducting the MTT assay with
a hepatocellular carcinoma cell line, have indicated the low
cytotoxicity of poly(L-lysine) dendrimer (Li et al., 2007). The
lower MTT levels and higher LDH values were observed only
with the relatively high concentrations unlikely to be used
in clinical applications. Even at such high concentrations the
toxicity remained within ranges accepted by the international
standards [International-Standards, 2009]. The data also revealed
no significant difference (P > 0.05) between 2 time intervals
incubation which is inconsistent with other studies that have
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 9 March 2019 | Volume 7 | Article 49
Al-azzawi et al. Brain Endothelial Cells Targeting Dendrons
FIGURE 9 | Analysis of FITC-labeled G0-, G1-dendron, and AEP-dendron by flow cytometry through FL1-H channel in comparison to negative control cells. The
density blots (A) show the uptake percentage of each molecule in comparison to the control. The single-parameter counting histograms (B) show clear peak shifting
from that of the control.
shown the cytotoxicity of dendrons is time dependent (Duncan
and Izzo, 2005). A previous study has provided a comprehensive
in vitro assessment of hydroxyl functional bis-MPA and cationic
PAMAM dendrimers and revealed that cytotoxicity is increasing
with time (Feliu et al., 2012). The type of cell line and the dendron
compositions could be the reasons beyond these controversial
observations. The results in this study suggest that molecules
could be internalized over a relatively short period of time (1 h
in vitro) and without harmful effect to the BBB endothelial cells.
Cellular uptake by the BBB endothelial cells was confirmed
by LSCM analysis of FITC-labeled carriers. The cellular binding
and uptake of the AMT-competent G0 and G1 dendrons were
shown. It has been suggested that dendrimers can successfully
be internalized by cells, possibly via adsorptive endocytosis here
facilitated by the combination of the overall positive charge of
the poly(epsilon-Lysine) dendron and the presence of a relatively
hydrophobic phenylalanine at the root of the carrier (Kolhe et al.,
2003; Patri and Simanek, 2012; Sadekar et al., 2013). After bEnd.3
cells were incubated with the RMT-competent AEP-dendron, a
more evident intracellular uptake of the FITC-labeled carrier
could be observed in comparison to the control and to the AMT-
competent carriers. These results supported the hypothesis of a
more efficient, receptor-mediated uptake of the AEP-decorated
dendron via the lipoprotein receptor. These findings were in
agreement with other studies which showed that nanoparticles
decorated with AEP were internalized by bEnd.3 cell line via
interaction with LDLr (Zensi et al., 2009; Wagner et al., 2012).
The findings obtained by LSCM, provided only a qualitative
assessment of the intracellular uptake of the carriers and required
a quantitative evaluation by flow cytometry. This study allowed to
assess the effect of the size and biospecificity of the carrier on cell
internalization. Noticeably, the uptake of the AMT-competent
G1-dendron was nearly the double of that measured in the case
of the G0-dendron, suggesting that the increased number of
amino branches and the higher number of positive charges on
G1 played a role more relevant than the hydrophobic domain
present at the root of the dendron. Indeed, it has previously
been shown that the cellular entry of G4-dendrimer was higher
than G3-dendrimer (Najlah and D’Emanuele, 2006) and the
cationic PAMAM dendrimers (G0-G4) permeability has been
found to increase with generation owing to a greater number
of peripheral positively-charged amino groups (Kitchens et al.,
2005). However, a significantly higher uptake of carriers by the
bEnd.3 cells was observed when a G0 dendron was root-modified
with the AEP-mimicking peptide. This suggests that this carrier
system entered the bEnd.3 cells, most likely by a receptor-
mediated pathway. This speculation is supported by previous
studies that have assessed the ApoE derived peptides intracellular
distribution that showed that their uptake is mediated by receptor
endocytosis (Re et al., 2010; Bana et al., 2014). The binding
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domain of the ApoE residue (141–150) has previously been found
to be able to induce a cellular uptake via LDLr- engagement
in primary cell cultures of brain tissue (X. Wang et al.,
1997). Furthermore, nanoliposomes decorated with the ApoE-
derived peptide have been shown to be efficiently internalized
by brain endothelium of rat after 30min incubation when
compared to free nanoliposome (Sauer et al., 2005). In addition,
nanoliposomes decorated with the ApoE-derived peptide (141–
150) have been shown to successfully enhance the brain uptake
of antioxidants (Gobbi et al., 2010) and curcumin (Re et al.,
2011). A further study has shown a specific cellular binding after
incubation of bEnd.3 cells with nanoparticles covalently linked
to ApoE in comparison to the unlinked nanoparticles using
confocal microscopy and flow cytometry analysis (Zensi et al.,
2009; Wagner et al., 2012).
This study has demonstrated that dendronised carriers are
able to be internalized by brain endothelia, and, to a greater
extent, when functionalized with AEP according to an RMT
strategy. This internalization is considered the initial step for
transporting bioactive materials into the brain. An attractive
aspect of the RMT strategy for CNS drug delivery is that it
targets specific organs, in turn, it bypasses, or reduced the
uptake by, other body tissues decreasing any undesirable systemic
effects. This is unlike other approaches which lack selective
brain targeting leading to higher distribution in the systemic
circulation and inadequate amounts delivered to the brain
(Jones and Shusta, 2007; Mager et al., 2017). Alternative entry
routes such as direct injection into the cerebrospinal fluid or
temporary opening to the BBB are limited by the requirement
of hospitalization, invasiveness and increased infection risk and
pathogen entry to the brain (Chen and Liu, 2012).
Peptides including AEP, are affordable, easily obtained and
characterized with their suitability to chemical modification
which opens up the possibility of applying them to a variety
of strategies where multiple functional groups for site-specific
conjugation can be added (Oller et al., 2016). Furthermore,
in the case of RMT, most peptide ligands neither compete
with endogenous compounds nor stay bound to the receptor
when compared to some antibodies that have been previously
used as carriers (Xiao and Gan, 2013; Oller et al., 2016). Thus
receptor-based BBB transporters have so far provided promising
achievements in preclinical brain delivery (Mager et al., 2017;
Molino et al., 2017).
Taking all the currently available evidence together, these
dendronised carrier systems produced using a solid-phase
synthesis optimized method have the potential to provide a novel
platform of BBB delivery systems for drugs (e.g., Flurbiprofen in
Alzheimer’s as previously shown, Al-Azzawi et al., 2018) or genes
that are currently ineffective or unavailable to the prescriber
due to their poor penetration of the BBB. Moreover, these
dendronised delivery systems are not only non-toxic but also
offers the potential to improve the drug’s bioavailability due to
their capability to couple large amounts of drugmolecules to their
branching ends.
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